InflaRx Reopens Case For Axed Phase 3 Drug For Rare Skin Disorder

InflaRx presented data analyses from a terminated Phase 3 study on the potential treatment for rare skin condition.

Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs

Detailed price information for Palvella Therapeutics Inc (PVLA-Q) from The Globe and Mail including charting and trades.
Fierce Pharma

After scrapped trial, InflaRx could tap partner to revive development of COVID drug in rare skin disorder

In turn, the company—which is broadly seeking to develop inflammatory drugs targeting the complement system—anticipates ...
Us Weekly

What Is Epidermolysis Bullosa? The Disorder That Killed Hannah Campbell’s Daughter, Explained

As influencer Hannah Campbell mourns the death of her 10-month-old daughter, Elliana Rose, she is also doing her part to fight the disease that affected her baby girl. “Our sweet girl Elliana Rose ...
Nasdaq

Quoin Pharmaceuticals Files Patent Applications for Topical Rapamycin Formulations Targeting Rare Skin Diseases

Quoin Pharmaceuticals Ltd. has announced the filing of U.S. and International patent applications for new topical formulations of rapamycin aimed at treating rare diseases such as microcystic ...
Nasdaq

Quoin Pharmaceuticals Files Patent Application for QRX003 to Treat Netherton Syndrome and Other Rare Skin Conditions

Quoin Pharmaceuticals Ltd. has filed a U.S. patent application for new topical formulations aimed at treating several skin diseases, specifically Netherton Syndrome (NS) and Peeling Skin Syndrome. The ...
Seeking Alpha

Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Palvella’s recently expanded rare disease pipeline now comprises QTORIN™-derived product candidates advancing in four serious, rare skin diseases that currently have no FDA-approved therapies Top-line ...
The American Journal of Managed Care

Using AI as Augmented Intelligence to Improve Rare Dermatologic Skin Diseases

Steven Daniel Daveluy, MD, FAAD, discussed how artificial intelligence (AI) can leverage extensive patient data and guide dermatologists to improve early diagnosis and treatment of rare dermatological ...